BellRing Brands Earnings Call Transcripts
Fiscal Year 2026
-
Q3 net sales and consumption exceeded expectations, but margins were pressured by inventory and freight costs. Full-year guidance was raised for sales but lowered for EBITDA, with price increases and cost-saving initiatives planned for 2027 to restore profitability.
-
Q2 net sales grew 2% year-over-year, but profitability was pressured by higher costs, unfavorable sales mix, and an $11M inventory charge. Full-year guidance was lowered, with flat to 2% net sales growth and 14% adjusted EBITDA margin expected as competitive and inflationary headwinds persist.
-
Q1 net sales grew 1% to $537M, with Dymatize up 16% and Premier down 1%. FY2026 guidance narrowed to 4%-6% sales growth and $425-$440M Adjusted EBITDA, reflecting higher input costs and increased promotions. CEO transition planned by September 2026.
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals passing by strong majorities. No shareholder questions were raised during the session.
Fiscal Year 2025
-
Convenient nutrition leader expects continued growth as category penetration rises, supported by strong brand equity, innovation, and expanded retail partnerships. Margin pressures from inflation and tariffs are being addressed through cost savings and pricing, with long-term targets intact.
-
Net sales grew 16% in fiscal 2025, with adjusted EBITDA margin at 20.8%. Guidance for 2026 anticipates 4%-8% sales growth and 18% EBITDA margin, with Q1 softness followed by stronger performance. Category leadership, innovation, and expanded distribution remain key growth drivers.
-
Net sales rose 6% to $548 million, with adjusted EBITDA at $120 million and strong category leadership. Guidance for fiscal 2025 was tightened, with continued margin pressure from input costs and tariffs expected in 2026. Premier Protein and innovation remain key growth drivers.
-
Q2 net sales rose 19% year-over-year, with Premier Protein driving strong growth and record market share. Fiscal 2025 guidance was reaffirmed, though Q3 faces headwinds from retailer inventory reductions and margin pressure from input costs. Robust innovation and expanded promotions support long-term growth.
-
Q1 net sales and adjusted EBITDA grew over 24% year-over-year, driven by Premier Protein's strong performance and expanded marketing. Full-year guidance was raised, with robust category growth and innovation fueling confidence despite input cost pressures.
Fiscal Year 2024
-
Net sales and adjusted EBITDA grew 20% and 30% year-over-year, respectively, with Premier Protein leading category growth and Dymatize showing strong international gains. Fiscal 2025 guidance calls for 12%-16% net sales growth and increased marketing spend, with margins pressured by input cost inflation.
-
Net sales rose 16% and adjusted EBITDA jumped 38% year-over-year, led by Premier Protein's strong growth and increased household penetration. Raised FY2024 guidance reflects robust demand, improved production capacity, and strong cash flow, with continued investment in marketing and innovation.